Published in Exp Hematol on March 01, 1979
Characterization of a virus that causes transient aplastic crisis. J Clin Invest (1984) 1.78
Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes. J Clin Invest (1985) 1.01
Chronic exposure to IFNα drives medullar lymphopoiesis towards T-cell differentiation in mice. Haematologica (2015) 0.78
Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science (2000) 10.98
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell (2000) 8.95
IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity (1998) 8.29
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity (1995) 6.91
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol (1983) 4.09
Binding of myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol (1993) 4.08
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med (1983) 3.83
Isolation of rat hepatocyte plasma membranes. I. Presence of the three major domains. J Cell Biol (1983) 3.76
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med (1998) 3.55
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol (1991) 3.32
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Concerning the mechanism of action of interferon. Proc Natl Acad Sci U S A (1966) 3.15
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
On-line computer quality control of antibiotic-sensitivity testing. N Engl J Med (1970) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 2.80
Inhibition of TRIC agents by virus-induced interferon. Proc Soc Exp Biol Med (1966) 2.78
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood (1999) 2.62
Physical properties of human interferon prepared in vitro and in vivo. Virology (1966) 2.62
A quasi-monoclonal mouse. Science (1996) 2.58
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 2.32
Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. J Infect Dis (1982) 2.29
Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest (1985) 2.28
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
Interferon inducers in vitro: difference in sensitivity to inhbitiros of RNA and protein synthesis. Science (1968) 2.16
T cell-independent interleukin 15Ralpha signals are required for bystander proliferation. J Exp Med (2001) 2.16
Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology (1988) 2.14
Isolation of rat hepatocyte plasma membranes. II. Identification of membrane-associated cytoskeletal proteins. J Cell Biol (1983) 2.11
Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. J Immunol (1975) 2.09
Cellular immunity and herpesvirus infections in cardiac-transplant patients. N Engl J Med (1977) 2.09
Measles in adults. An unforeseen consequence of immunization? JAMA (1976) 2.08
Patient compliance and drug failure in protease inhibitor monotherapy. JAMA (1996) 2.06
Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med (1978) 2.04
Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers. Virology (1968) 1.96
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol (1989) 1.92
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Induction of circulating interferon by synthetic anionic polymers of known composition. Nature (1967) 1.92
Interferon and cytomegalovirus in vivo and in vitro. Proc Soc Exp Biol Med (1967) 1.85
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest (1991) 1.85
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis (1995) 1.77
The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon. J Clin Invest (1971) 1.75
PPD-stimulated interferon: in vitro macrophage-lymphocyte interaction in the production of a mediator of cellular immunity. Cell Immunol (1971) 1.75
Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol (1997) 1.74
Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med (1973) 1.73
A useful quantitative semimicromethod for viral plaque assay. Proc Soc Exp Biol Med (1973) 1.73
Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Proc Natl Acad Sci U S A (1972) 1.73
Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J Virol (1985) 1.73
The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg (1990) 1.72
Viral infections in man associated with acquired immunological deficiency states. Fed Proc (1972) 1.70
Conservation of heterochromatin protein 1 function. Mol Cell Biol (2000) 1.70
Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes. J Clin Microbiol (1995) 1.69
An artificial intelligence program to advise physicians regarding antimicrobial therapy. Comput Biomed Res (1973) 1.69
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS (1999) 1.68
Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus. Infect Immun (1976) 1.67
Interferon, antibody, and other host factors in herpes zoster. J Clin Invest (1972) 1.64
The immunosuppressive effect of type II mouse interferon preparations on antibody production. Cell Immunol (1977) 1.64
Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. J Immunol (1974) 1.60
Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol (1984) 1.60
Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med (1984) 1.58
Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev (1995) 1.58
Bis-DEAE-fluorenone: mechanism of antiviral protection and stimulation of interferon production in the mouse. J Infect Dis (1971) 1.56
Herpes Zoster-Varicella infections and lymphoma. Ann Intern Med (1972) 1.54
Current concepts of interferon and interferon induction. Annu Rev Med (1970) 1.53
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation (1999) 1.52
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis (1978) 1.51
Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology (1981) 1.49
The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86. Virology (1989) 1.49
Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to Herpes simplex antigen. J Immunol (1975) 1.49
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol (1997) 1.48
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol (1995) 1.48
Integration and the performance of healthcare networks: do integration strategies enhance efficiency, profitability, and image? Int J Integr Care (2001) 1.48
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
Antioxidant supplementation decreases oxidative DNA damage in human lymphocytes. Cancer Res (1996) 1.46
Hereditary occurrence of cystic disease of the renal medulla. N Engl J Med (1966) 1.46
Multiple adnexal tumors and a parotid basal cell adenoma. J Am Acad Dermatol (1991) 1.44
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr (1994) 1.44
Diagnosis of cytomegalovirus pneumonia in compromised hosts. Am J Med (1976) 1.44
Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med (1978) 1.44
Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Cell Immunol (1978) 1.43
Requirement of a stable secondary structure for the antiviral activity of polynucleotides. Nature (1969) 1.43
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis (1991) 1.43
Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA (1982) 1.42
IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression. EMBO J (1989) 1.42